Showing results (111-120 of 202) with videos related to
Sort By:
Pageof 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 15, 2015
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United StatesMichael P Girouard, Paul E Sax, Robert A Parker, et al.The Journal of Infectious Diseases|August 6, 2004
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjectsRonald Swanstrom, Ronald J Bosch, David Katzenstein, et al.Transfusion|November 20, 2020
Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curveRobert A DeSimone, Victoria A Costa, Kathleen Kane, et al.Journal of Clinical Microbiology|June 5, 2009
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virionsNoriaki Hosoya, Zhaohui Su, Timothy Wilkin, et al.AIDS (London, England)|December 29, 2004
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group studyDavid W Haas, Heather J Ribaudo, Richard B Kim, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2007
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)Cecilia M Shikuma, Yang Yang, Marshall J Glesby, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysisHeather J Ribaudo, Kimberly Y Smith, Gregory K Robbins, et al.Open Forum Infectious Diseases|September 1, 2020
COVID-19 in Hospitalized Adults With HIVKate Stoeckle, Carrie D Johnston, Deanna P Jannat-Khah, et al.Lancet (London, England)|August 8, 2006
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysisMargaret T May, Jonathan A C Sterne, Dominique Costagliola, et al.Journal of Virology|April 12, 2012
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressuresAthe M N Tsibris, Zixin Hu, Roger Paredes, et al.Pageof 21